• Healthcare Huddle
  • Posts
  • Prescription Predicament: How Three New Models are Tackling Drug Prices

Prescription Predicament: How Three New Models are Tackling Drug Prices

Huddle+ | Huddle #Trends

The Centers for Medicare and Medicaid Services revealed three experimental models to improve drug affordability and access. Each model is unique, targeting different areas within the drug market that contribute to high drug prices.

While these are experimental models, they have the potential to reshape the drug market and improve the patient experience. So, let’s talk about it.

In this article, I’ll briefly discuss the current state of drug prices in the U.S., dive into CMS’s three experimental models to lower drug prices, and discuss key players tackling drug prices.

Subscribe to Huddle+ to read the rest.

Become a paying subscriber of Huddle+ to get access to this post and other subscriber-only content.

Already a paying subscriber? Sign In

A subscription gets you:
Full access to Sunday's Healthcare Huddle Newsletter
Thursday's Inefficiency Insights Newsletter
Monthly Huddle #Trends reports
Huddle University (coming soon)